Danish pharmaceutical company Novo Nordisk has launched its blockbuster diabetes drug Ozempic in India as demand grows for treatments that address type 2 diabetes and related weight-management needs. The drug, a once-weekly injectable therapy for type 2 diabetes, is now available in the country in three strengths — 0.25 mg, 0.5 mg and 1 mg — with the lowest dose priced at ₹8,800 per month and higher doses at ₹10,170 and ₹11,175 per month respectively.
Novo Nordisk received regulatory approval in September to import and sell Ozempic in India, marking a strategic expansion into the world’s most populous market, where the number of people living with type 2 diabetes ranks second globally after China and obesity rates are rapidly increasing. Analysts cited in industry reporting have projected that the global weight-loss and related treatment market could be worth as much as $150 billion annually by the end of the decade, making India a key focus for global drugmakers competing in this space.
Though Ozempic is approved primarily for diabetes, it has become widely used off-label for its appetite-suppressing effects that support weight loss, complementing Novo Nordisk’s existing GLP-1 portfolio in India that also includes products such as Wegovy targeted at obesity management.
